Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Emergent BioSolutions Inc EBS

Healthcare Biotechnology
Emergent BioSolutions, Inc. is a life sciences company. It is focused on providing preparedness and response solutions addressing accidental, deliberate and naturally occurring public health threats. Its solutions include a product portfolio, a product development portfolio, and a Bioservices portfolio. Its segments include Commercial Products, MCM Products, and Services Segment. Commercial... see more

Recent & Breaking News (NYSE:EBS)

Emergent BioSolutions Awarded $23 Million to Develop Novel Multi-Drug Auto-Injector for U.S. Department of Defense

GlobeNewswire July 31, 2017

Emergent BioSolutions Secures Exclusive Worldwide Rights to Valneva’s Zika Vaccine Technology

GlobeNewswire July 26, 2017

Emergent BioSolutions to Release Second Quarter 2017 Financial Results and Conduct a Conference Call on August 3, 2017

GlobeNewswire July 20, 2017

Emergent BioSolutions to Acquire Raxibacumab, an FDA-Approved Anthrax Monoclonal Antibody, From GSK

GlobeNewswire July 19, 2017

Emergent BioSolutions to Acquire ACAM2000® Business From Sanofi

GlobeNewswire July 14, 2017

Emergent BioSolutions to Hold Annual Meeting of Stockholders Thursday May 25, 2017 at 9:00 AM EDT; Webcast Will be Available

GlobeNewswire May 11, 2017

Emergent BioSolutions Unveils Its Expanded Center for Innovation in Advanced Development and Manufacturing in Baltimore

GlobeNewswire May 10, 2017

Emergent BioSolutions to Unveil its Expanded Center for Innovation in Advanced Development and Manufacturing Supported through Public-Private Partnership with BARDA

GlobeNewswire May 9, 2017

Emergent BioSolutions Reports First Quarter 2017 Financial Results; Reaffirms 2017 Guidance

GlobeNewswire May 4, 2017

EBS INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of Commencement of a Class Action Involving Emergent Biosolutions Inc. and a Lead Plaintiff Deadline of September 19, 2016

Business Wire August 22, 2016

Brower Piven Alerts Shareholders of Upcoming Deadline in Class Action Lawsuit and Encourages Those with Substantial Losses from Investment in Emergent BioSolutions, Inc. to Contact the Firm

Business Wire August 21, 2016

EMERGENT SHAREHOLDER ALERT By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit against Emergent Biosolutions, Inc. - EBS

Business Wire August 19, 2016

EBS INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of Commencement of a Class Action Involving Emergent Biosolutions Inc. and a Lead Plaintiff Deadline of September 19, 2016

GlobeNewswire August 17, 2016

Emergent BioSolutions Receives FDA Approval for Large-Scale Manufacturing of BioThrax in Building 55

GlobeNewswire August 15, 2016

SHAREHOLDER ALERT: Holzer & Holzer Files Securities Class Action Lawsuit Against Emergent BioSolutions; Reminds Investors of September 19, 2016 Deadline

Business Wire August 15, 2016

Emergent BioSolutions Announces Conversion Rate Adjustment to 2.875% Convertible Senior Notes Due 2021 Following Spin-Off of Aptevo Therapeutics

GlobeNewswire August 12, 2016

EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Emergent BioSolutions, Inc. - EBS

GlobeNewswire August 12, 2016

INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Emergent Biosolutions Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of September 19, 2016 – EBS

GlobeNewswire August 12, 2016

SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Emergent Biosolutions, Inc. To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit – EBS

GlobeNewswire August 11, 2016

Glancy Prongay & Murray Announces the Filing of a Securities Class Action on Behalf of Emergent BioSolutions, Inc. Investors and Encourages Investors to Contact the Firm

Business Wire August 11, 2016